Rising Immunization Efforts Boost Global Typhoid Vaccine Market Growth

According to a study published in Lancet: Infectious Diseases, typhoid infects 21.6 million people worldwide and kills an estimated 200,000 people each year. Furthermore, economic instability in Latin America and other developing economies has resulted in poor sanitation and restricted access to clean water and food, putting people at risk of contracting typhoid. Salmonella typhi produces typhoid fever, which causes symptoms such as a high temperature, headache, loss of appetite, constipation, and nausea. Typhoid fever is primarily spread in areas with poor sanitation and contaminated water. Typhoid fever vaccines are biological formulations that provide immunity and protection against typhoid fever in humans.

Apr 21, 2025 - 10:57

0 5

Global Typhoid Vaccine Market Segmentation, By Type (Live Attenuated Vaccine, Monovalent Typhoid Vaccines, Capsular Polysaccharide Vaccines, Conjugate Vaccine, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2032

Access Full 350 Pages PDF Report @

https://www.databridgemarketresearch.com/reports/global-typhoid-vaccine-market

Introduction

Typhoid fever remains a persistent public health challenge, particularly in low- and middle-income countries with inadequate sanitation and limited access to clean water. Caused by the bacterium Salmonella typhi, the disease can lead to severe illness and even death if untreated. Typhoid vaccines offer effective protection and have become a vital component of preventive healthcare, especially in endemic regions. The global typhoid vaccine market has experienced notable growth as global health authorities, governments, and pharmaceutical companies intensify their efforts to combat the disease through immunization.

Market Size

Global typhoid vaccine market size was valued at USD 434.93 million in 2024 and is projected to reach USD 973.78 million by 2032, with a CAGR of 10.60% during the forecast period of 2025 to 2032.

Market Share

Asia-Pacific accounts for the largest share of the global typhoid vaccine market, representing nearly 60% of the total demand. This dominance is due to the high prevalence of typhoid fever in countries like India, Pakistan, Bangladesh, and Indonesia. National immunization programs and mass vaccination campaigns in these countries have led to widespread adoption of TCVs.

Africa holds the second-largest market share, accounting for approximately 20%. Many countries in Sub-Saharan Africa face similar issues with water sanitation and hygiene, making typhoid vaccines a critical intervention. The region has seen increasing vaccine deployment through support from Gavi and WHO prequalification programs.

Latin America and the Middle East contribute about 10% of the market, while North America and Europe collectively make up the remaining 10%. Although typhoid is less common in these regions, demand arises from travelers, military personnel, and migrant populations.

Market Trends

One of the significant trends shaping the typhoid vaccine market is the shift toward typhoid conjugate vaccines (TCVs). Unlike older polysaccharide vaccines, TCVs offer longer-lasting immunity, are effective in children under two years of age, and can be integrated into routine childhood immunization schedules. WHO's endorsement of TCVs has accelerated their adoption worldwide.

Another trend is the increased emphasis on combination vaccines. Manufacturers are working to develop multivalent vaccines that combine protection against typhoid with other diseases such as paratyphoid, cholera, and hepatitis. These vaccines improve compliance and reduce logistical costs in immunization programs.

Advancements in cold chain infrastructure and vaccine storage technologies are expanding the market’s reach to remote and underserved areas. Innovations such as thermostable formulations are improving the efficiency of vaccine delivery in regions with limited refrigeration capabilities.

Digital health tools and surveillance systems are also influencing market trends by improving disease monitoring and vaccine coverage assessment. Governments and global health agencies are using real-time data to plan and execute more effective vaccination campaigns.

Public-private partnerships between governments, NGOs, and pharmaceutical companies are playing a crucial role in market development. These collaborations are focused on research, clinical trials, distribution, and education to increase vaccine uptake.

Market Growth

The typhoid vaccine market is undergoing steady growth driven by a mix of public health policy changes and scientific advancements. Increased global focus on combating antimicrobial resistance (AMR) has underscored the importance of preventing diseases like typhoid, which are commonly treated with antibiotics. Immunization is viewed as a key strategy to reduce antibiotic use and slow the development of resistance.

The inclusion of TCVs in routine immunization schedules by countries like Pakistan, Nepal, and Liberia has contributed significantly to market growth. Mass campaigns targeting children between 6 months and 15 years have created a sustained demand for vaccines.

Urbanization and population growth in typhoid-endemic regions have increased the risk of outbreaks, pushing governments to adopt proactive immunization strategies. Global travel and migration also pose a risk for disease spread, thereby expanding the vaccine market in non-endemic regions.

Increased government funding and international support are accelerating market expansion. For instance, Gavi’s financial backing has enabled countries with limited healthcare budgets to roll out nationwide TCV campaigns, leading to higher procurement volumes and improved market accessibility.

The pediatric population is the largest segment contributing to market growth. With TCVs offering safe and effective protection for infants and young children, vaccination rates are steadily increasing. School-based programs and child health days are being used to boost coverage in hard-to-reach areas.

Market Demand

Demand for typhoid vaccines is high in regions with poor sanitation infrastructure and limited access to clean drinking water. Asia and Africa remain the key markets due to their vulnerability to typhoid outbreaks. Immunization drives in urban slums, refugee camps, and conflict-affected areas are sustaining year-round demand.

The demand for TCVs is outpacing that of traditional polysaccharide vaccines. Health authorities are opting for TCVs because of their superior efficacy, age suitability, and compatibility with routine childhood vaccination schedules.

Travelers from developed countries also contribute to market demand. Travel clinics and health authorities recommend typhoid vaccines for individuals visiting endemic regions, especially those traveling for extended periods, humanitarian work, or military deployment.

In the private healthcare sector, growing health consciousness and rising disposable incomes in developing countries have led to increased demand for preventive vaccines, including typhoid.

Pharmaceutical companies are also witnessing rising demand from international agencies like UNICEF and the Pan American Health Organization (PAHO), which procure vaccines for large-scale deployment in vulnerable regions.

Factors Driving Growth

The growing burden of typhoid fever in endemic regions is the primary factor driving market growth. With millions of new cases reported annually and rising concerns about drug-resistant strains, vaccination remains a top priority for disease prevention.

Government initiatives and global health campaigns are fueling growth. Countries implementing universal immunization programs and school-based vaccination strategies are creating long-term demand for typhoid vaccines.

The development and adoption of TCVs have transformed the market landscape. TCVs are safe for infants, offer long-lasting immunity, and require fewer doses, making them a preferred choice for national immunization programs.

Increased awareness about travel-related health risks is contributing to vaccine uptake in developed countries. Public health advisories and recommendations by CDC and WHO are encouraging travelers to get vaccinated before visiting high-risk areas.

Rising healthcare investments, especially in Asia and Africa, are improving access to vaccines. Strengthened cold chain systems, logistics infrastructure, and healthcare delivery networks are enhancing distribution and coverage.

Support from international organizations such as Gavi, WHO, and UNICEF is enabling large-scale procurement and distribution of vaccines, especially in low-income countries. Their funding and policy advocacy are crucial to expanding market reach and vaccine affordability.

Technological advancements in vaccine production and delivery are reducing costs and improving efficiency. Innovations such as single-dose vials, prefilled syringes, and thermostable vaccines are making immunization more convenient and scalable.

Conclusion

The global typhoid vaccine market is poised for sustained growth as the world intensifies efforts to prevent the spread of typhoid fever. Increasing adoption of TCVs, strong support from global health organizations, and heightened awareness of public health risks are shaping the future of this critical vaccine segment. As innovations continue and access expands, typhoid vaccines will play an even greater role in safeguarding vulnerable populations and reducing the global disease burden.

Browse Trending Reports: